Literature DB >> 25438244

Amino acid N-acetylation: metabolic elimination of symmetric dimethylarginine as symmetric N(α)-acetyldimethylarginine, determined in human plasma and urine by LC-MS/MS.

Jens Martens-Lobenhoffer1, Stefanie M Bode-Böger2.   

Abstract

Symmetric dimethylarginine (SDMA) is considered as a parameter for renal insufficiency superior to the established creatinine. Its applicability for this purpose may be hampered by the fact that SDMA is not exclusively eliminated via the renal route but is also metabolized. In this work, we present a method for the quantification of the metabolite symmetric Nα-acetyldimethylarginine (Ac-SDMA) by LC-MS/MS in human plasma and urine. D6-Ac-SDMA was used as internal standard. After simple protein precipitation and in-line clean up, the analytes were separated on a porous graphitic carbon column. Calibration functions were linear in the ranges of 0.2-80 nM for plasma and 10-4000 nM for urine. The quantification was matrix independent and the precisions and accuracies were better than 8% at all concentration levels. Concentration found in human plasma and urine was 3.51 nM and 558 nM, respectively, with marked inter-individual differences.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  LC–MS/MS; Plasma; Symmetric N(α)-acetyldimethylarginine; Symmetric dimethylarginine; Urine

Mesh:

Substances:

Year:  2014        PMID: 25438244     DOI: 10.1016/j.jchromb.2014.11.009

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  7 in total

Review 1.  Epimetabolites: discovering metabolism beyond building and burning.

Authors:  Megan R Showalter; Tomas Cajka; Oliver Fiehn
Journal:  Curr Opin Chem Biol       Date:  2017-02-16       Impact factor: 8.822

2.  Symmetric dimethylarginine (SDMA) outperforms asymmetric dimethylarginine (ADMA) and other methylarginines as predictor of renal and cardiovascular outcome in non-dialysis chronic kidney disease.

Authors:  Insa E Emrich; Adam M Zawada; Jens Martens-Lobenhoffer; Danilo Fliser; Stefan Wagenpfeil; Gunnar H Heine; Stefanie M Bode-Böger
Journal:  Clin Res Cardiol       Date:  2017-11-03       Impact factor: 5.460

Review 3.  Asymmetric and Symmetric Dimethylarginine as Risk Markers for Total Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis of Prospective Studies.

Authors:  Sabrina Schlesinger; Svenja R Sonntag; Wolfgang Lieb; Renke Maas
Journal:  PLoS One       Date:  2016-11-03       Impact factor: 3.240

4.  Plasma Symmetric Dimethylarginine Concentration in Dogs with Acute Kidney Injury and Chronic Kidney Disease.

Authors:  D P Dahlem; R Neiger; A Schweighauser; T Francey; M Yerramilli; E Obare; S M L Steinbach
Journal:  J Vet Intern Med       Date:  2017-03-30       Impact factor: 3.333

Review 5.  Novel Biomarkers in the Diagnosis of Chronic Kidney Disease and the Prediction of Its Outcome.

Authors:  Jacek Rysz; Anna Gluba-Brzózka; Beata Franczyk; Zbigniew Jabłonowski; Aleksandra Ciałkowska-Rysz
Journal:  Int J Mol Sci       Date:  2017-08-04       Impact factor: 5.923

Review 6.  The Second Life of Methylarginines as Cardiovascular Targets.

Authors:  Natalia Jarzebska; Arduino A Mangoni; Jens Martens-Lobenhoffer; Stefanie M Bode-Böger; Roman N Rodionov
Journal:  Int J Mol Sci       Date:  2019-09-17       Impact factor: 5.923

7.  Biomarkers for chronic kidney disease in dogs: a comparison study.

Authors:  Joonyoung Kim; Chang-Min Lee; Ha-Jung Kim
Journal:  J Vet Med Sci       Date:  2020-07-23       Impact factor: 1.267

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.